PANTHERx Rare® Pharmacy Chosen as Partner by Alnylam Pharmaceuticals for OXLUMO™ (lumasiran) for the Treatment of Primary Hyperoxaluria Type 1 (PH1) to Lower Urinary Oxalate Levels
Read the Official PANTHERx Press Release. PANTHERx® Rare Pharmacy announces that it has been selected by Alnylam Pharmaceuticals, the leading RNAi therapeutics company, as a very limited distribution pharmacy partner …